📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Risk factors for non-participation in ivermectin and dihydroartemisinin-piperaquine mass drug administration for malaria control in the MASSIV trial (2024)

First Author: Kositz C

Attributed to: Epidemiological and statistical research on health problems of low and middle-income countries: MRC Tropical Epidemiology Group (TEG) funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1186/s12936-024-04878-2

Publication URI: http://dx.doi.org/10.1186/s12936-024-04878-2

Type: Journal Article/Review

Parent Publication: Malaria Journal

Issue: 1